Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - March 2016

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Bivalirudin- Lyophilized Powder for Injection
Canagliflozin - Tablets
Clindamycin - Capsules
Clindamycin - Injection and Solution in Galaxy Plastic Containers
Clonazepam -Tablets
Efavirenz - Capsules and Tablets
Etonogestrel - Implant
Etonogestrel - Implants
Filgrastim-sndz
Fulvestrant - Solution for Injection
Furosemide - Tablets, Injection
Hydroxyurea - Capsules
Lomitapide - Capsules
Mecasermin [rDNA origin] injection
Ocriplasmin - Intravitreal Injection
Oxybutynin Hydrochloride -Transdermal System
Risperidone - Tablets, Oral Solution and Orally Disintegrating Tablets
Ruxolitinib - Tablet
Sevelamer - Powder for Oral Suspension
Sevelamer - Tablets
Trastuzumab - Intravenous Infusion
Zoledronic acid - Injection

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Get Health and Wellness Secrets from Our Engaging eBooks
Stay Connected
Available on the Android Market Available on the App Store